Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin

• Published in: PharmacoEconomics Vol. 10; no. 1; p. 79
• Main Authors: Craig, A M, Davey, P, Malek, M, Murray, F
• Format: Journal Article
• Language: English
• Published: New Zealand 01.07.1996
• Subjects: Adult; Amoxicillin - administration & dosage; Amoxicillin - economics; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - economics; Clarithromycin - administration & dosage; Clarithromycin - economics; Costs and Cost Analysis; Decision Support Techniques; Drug Therapy, Combination - administration & dosage; Drug Therapy, Combination - economics; Duodenal Ulcer - drug therapy; Duodenal Ulcer - economics; Helicobacter Infections - drug therapy; Helicobacter Infections - economics; Helicobacter pylori; Humans; Middle Aged; Models, Economic; Omeprazole - administration & dosage; Omeprazole - economics

In patients with duodenal ulcer, omeprazole plus clarithromycin (OC) has achieved Helicobacter pylori eradication rates of about 80%, compared with 50% for omeprazole plus amoxicillin (OA). The drug acquisition costs for OC are 102.92 pounds sterling (pounds) compared with 38.96 pounds for OA using...